Äèñêóññèîííûé Êëóá Ðóññêîãî Ìåäèöèíñêîãî Ñåðâåðà
MedNavigator.ru - Ïîèñê è ïîäáîð ëå÷åíèÿ â Ðîññèè è çà ðóáåæîì

Âåðíóòüñÿ   Äèñêóññèîííûé Êëóá Ðóññêîãî Ìåäèöèíñêîãî Ñåðâåðà > Ôîðóìû âðà÷åáíûõ êîíñóëüòàöèé > Íåâðîëîãèÿ è íåéðîõèðóðãèÿ > Ôîðóì äëÿ îáùåíèÿ âðà÷åé íåâðîëîãîâ è íåéðîõèðóðãîâ

Ôîðóì äëÿ îáùåíèÿ âðà÷åé íåâðîëîãîâ è íåéðîõèðóðãîâ Ôîðóì ïðåäíàçíà÷åí äëÿ îáùåíèÿ âðà÷åé ìåæäó ñîáîé.

Îòâåò
 
Îïöèè òåìû Ïîèñê â ýòîé òåìå Îïöèè ïðîñìîòðà
  #1  
Ñòàðûé 06.08.2018, 18:48
Àâàòàð äëÿ Niko
Niko Niko âíå ôîðóìà
ÂÐÀ×
 
Ðåãèñòðàöèÿ: 29.04.2016
Ãîðîä: Ðîññèÿ
Ñîîáùåíèé: 923
Ñêàçàë(à) ñïàñèáî: 17
Ïîáëàãîäàðèëè 305 ðàç(à) çà 286 ñîîáùåíèé
Çàïèñåé â äíåâíèêå: 2
Niko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåNiko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåNiko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåNiko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåNiko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåNiko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåNiko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåNiko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåNiko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Èøåìè÷åñêèé èíñóëüò/ÒÈÀ â ìîëîäîì âîçðàñòå.

Óâàæàåìûå êîëëåãè, íåò ëè ó âàñ õîðîøèõ èñòî÷íèêîâ íà àëãîðèòì ïîèñêà ïðè÷èíû èøåìè÷åñêîãî èíñóëüòà/ÒÈÀ ó äåòåé/ìîëîäûõ?
Îòâåòèòü ñ öèòèðîâàíèåì
  #2  
Ñòàðûé 06.08.2018, 19:00
Àâàòàð äëÿ Dr.Vad
Dr.Vad Dr.Vad âíå ôîðóìà
Ìîäåðàòîð ôîðóìà ïî ãåìàòîëîãèè
      
 
Ðåãèñòðàöèÿ: 16.01.2003
Ãîðîä: Õüþñòîí, Òåõàñ
Ñîîáùåíèé: 80,291
Ïîáëàãîäàðèëè 33,189 ðàç(à) çà 31,539 ñîîáùåíèé
Dr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
ãðàôè÷åñêèé àëãîðèòì êðèïòîãåííîãî èíñóëüòà èç ÍÅÉÌà çäåñü:
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]

ïðî äåòåé íå ãðàôè÷åñêèé, íî â ãðàäàöèÿõ â ãëàâå 6 INVESTIGATIONS (ñòð.15)

Diagnosis and Acute Management of Childhood Stroke
CLINICAL GUIDELINE 2017
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
__________________
Èñêðåííå,
Âàäèì Âàëåðüåâè÷.
Îòâåòèòü ñ öèòèðîâàíèåì
  #3  
Ñòàðûé 07.08.2018, 18:21
Àâàòàð äëÿ Niko
Niko Niko âíå ôîðóìà
ÂÐÀ×
 
Ðåãèñòðàöèÿ: 29.04.2016
Ãîðîä: Ðîññèÿ
Ñîîáùåíèé: 923
Ñêàçàë(à) ñïàñèáî: 17
Ïîáëàãîäàðèëè 305 ðàç(à) çà 286 ñîîáùåíèé
Çàïèñåé â äíåâíèêå: 2
Niko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåNiko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåNiko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåNiko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåNiko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåNiko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåNiko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåNiko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåNiko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Ñïàñèáî áîëüøîå.
Îòâåòèòü ñ öèòèðîâàíèåì
  #4  
Ñòàðûé 08.08.2018, 16:43
Àâàòàð äëÿ Niko
Niko Niko âíå ôîðóìà
ÂÐÀ×
 
Ðåãèñòðàöèÿ: 29.04.2016
Ãîðîä: Ðîññèÿ
Ñîîáùåíèé: 923
Ñêàçàë(à) ñïàñèáî: 17
Ïîáëàãîäàðèëè 305 ðàç(à) çà 286 ñîîáùåíèé
Çàïèñåé â äíåâíèêå: 2
Niko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåNiko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåNiko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåNiko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåNiko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåNiko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåNiko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåNiko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåNiko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Ïðî÷¸ë ñòàòüè. Ó ìåíÿ åñòü âîïðîñû. Áóäó ðàä ïîìîùè â ðàçáîðå íå òîëüêî íåâðîëîãîâ, íî è ñìåæíûõ ñïåöèàëèñòîâ. Ìîæíî îòâå÷àòü íå íà âñå âîïðîñû.
1)Êàêèå ïîêàçàíèÿ ìîãóò áûòü ê ïðîâåäåíèþ ðåíòãåíîãðàììû ë¸ãêèõ (áåç ñîîòâåòñòâóþùåé êëèíèêè ñî ñòîðîíû ë¸ãêèõ): ëþáîé èíñóëüò, êðèïòîãåííûé èíñóëüò, îñòðûé ïåðèîä ëþáîãî èíñóëüòà èëè íåò ïîêàçàíèé?  ññûëêàõ ðåíòãåíîãðàììû íå áûëî, îäíàêî â ìîèõ ïðåäûäóùèõ êîíñïåêòèðîâàíèÿõ îíà áûëà.

2)Êàêèå ïîêàçàíèÿ ìîãóò áûòü ê ïðîâåäåíèþ áèîõèìè÷åñêèõ àíàëèçîâ êðîâè (ìî÷åâèíà, êðåàòèíèí, ýëåêòðîëèòû, îñìîëÿðíîñòü, ãëþêîçà), à òàêæå îáùåãî àíàëèçà ìî÷è: ÿ äóìàþ, ÷òî ýòî òîëüêî îñòðûé ïåðèîä èíñóëüòà è äëÿ ïîñëåäóþùåé äèàãíîñòèêè (äàæå êðèïòîãåííûõ) ýòè ïîêàçàòåëè íå òðåáóþòñÿ (êðîìå ãëþêîçû), ÿ ïðàâ?

3)Ïðè ÎÎÎ ìåõàíèçì îáðàçîâàíèÿ èíñóëüòà èñêëþ÷èòåëüíî ïóò¸ì ìèãðàöèè ýìáîëà èç áîëüøîãî êðóãà êðîâîîáðàùåíèÿ èëè ñàìî ÎÎÎ òàêæå ÿâëÿåòñÿ îäíîé èç ïðè÷èí îáðàçîâàíèÿ òðîìáà? Ó÷èòûâàÿ òî, ÷òî ýòà àíîìàëèÿ âñòðå÷àåòñÿ ÷àñòî è åñëè êîàãóëÿöèîííûå òåñòû â íîðìå, ìû ìîæåì ïðîäîëæàòü ñ÷èòàòü èíñóëüò êðèïòîãåííûì?

4)ïðè êðèïòîãåííîì èíñóëüòå ìû äîëæíû íàçíà÷àòü òåðàïèþ ñòàòèíàìè è àíòèàãðåãàíòàìè?

5)×òî çíà÷èò: Transcranial Doppler monitoring for emboli ? È íàñêîëüêî òàêàÿ ïðîöåäóðà äîñòóïíà?

6)Prolonged (2–4 wk) outpatient cardiac telemetry – êàê ýòî ïðîâîäèòñÿ è íàñêîëüêî ýòî äîñòóïíûé ìåòîä?

7) Êàêèå òåñòû íà âàñêóëèò íóæíî ñäàâàòü?

8) Êàêèå òåñòû íà àðòåðèàëüíóþ, à êàêèå íà âåíîçíóþ ãèïåðêîàãóëÿöèþ?
òóò ïåðå÷èñëþ àíàëèçû èç ñâîèõ ïðåäûäóùèõ êîíñïåêòèðîâàíèé: ôèáðèíîãåí, àíòèòåëà ê êàðäèîëèïèíó, âîë÷àíî÷íûé àíòèêîàãóëÿíò, àò. ê áåòà2ãëèêîïðîòåèíó, ïðîòèåèí Ñ, ïðîòåèí S, àíòèòðîìáèí III, àêòèâèðîâàííûé ïðîòåèí C, ôàêòîð V Leiden, ïðîòðîìáèí G20210A, ôàêòîð ìóòàöèè MTHFR TT677 , ãîìîöèñòåèí. Êóðñèâîì îáîçíà÷èë òå, êîòîðûå íå íàø¸ë â ññûëêàõ, à æèðíûì - òå, ÷òî íå áûëè â ìîèõ ïðåäûäóùèõ êîíñïåêòàõ.

9)ÌÐ-âåíîãðàôèÿ, áåëêîâûå ôðàêöèè, RPR – òåñò(ñèôèëèñ), àò ê ÂÈ×, ëèïèäîãðàììà, àíòèíóêëåàðíûå àíòèòåëà - ÷òî âû ìîæåòå ñêàçàòü ïî ïîâîäó ýòèõ îáñëåäîâàíèé?

10)The stroke may be considered to be cryptogenic
after standard evaluation when clinical
examination and brain imaging suggest a superficial
or large, deep cerebral infarct, but none
of the above routine vessel-imaging, cardiac, or
hematologic tests has revealed a probable cause.
Patients with a small, deep infarct also may be
considered to have cryptogenic stroke if they are
younger than 50 years of age, have no standard
vascular risk factors, and have no white-matter
hyperintensities or prior small, deep infarcts.
Ïî÷åìó ïðè ïðåäûäóùåì ëàêóíàðíîì îäíîì èíñóëüòå ìû íå ìîæåì ãîâîðèòü, ÷òî ïîñëåäóþùèé êðèïòîãåííûé?

11) Òåñòû íà æåëåçîäåôèöèò íóæíû òîëüêî äåòÿì? È êàê âûÿâëåííûé æåëåçîäåôèöèò ìîæåò ïîâëèÿòü íà ïîèñê ýòèîëîãèè èíñóëüòà?
Îòâåòèòü ñ öèòèðîâàíèåì
  #5  
Ñòàðûé 08.08.2018, 17:11
Àâàòàð äëÿ Dr.Vad
Dr.Vad Dr.Vad âíå ôîðóìà
Ìîäåðàòîð ôîðóìà ïî ãåìàòîëîãèè
      
 
Ðåãèñòðàöèÿ: 16.01.2003
Ãîðîä: Õüþñòîí, Òåõàñ
Ñîîáùåíèé: 80,291
Ïîáëàãîäàðèëè 33,189 ðàç(à) çà 31,539 ñîîáùåíèé
Dr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Ïðî òðîìáîôèëèþ: âñå áîëüøå è áîëüøå ïóáëèêàöèé/ìíåíèé, ÷òî êðîìå àíòèôîñôîëèïèäíîãî ñèíäðîìà, íèêàêèå äðóãèå òåñòû íå íóæíû - íèêàê íå âëèÿþò íà âåäåíèå ïàöèåíòà è îòíèìàþò ëèøíèå ñðåäñòâà ïðè îáñëåäîâàíèè, íàïðèìåð:

Low prevalence and diagnostic yield of various thrombophilic disorders does not support strongly the routine screening of the general population.
---
Role of Investigating Thrombophilic Disorders in Young Stroke
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]

systematic testing for thrombophilia is unlikely to improve the outcome and to be cost-effective in young stroke patients...
---
Testing for thrombophilia in cryptogenic stroke in the young: is it useful?
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
__________________
Èñêðåííå,
Âàäèì Âàëåðüåâè÷.
Îòâåòèòü ñ öèòèðîâàíèåì
  #6  
Ñòàðûé 08.08.2018, 17:53
Àâàòàð äëÿ Dr.Vad
Dr.Vad Dr.Vad âíå ôîðóìà
Ìîäåðàòîð ôîðóìà ïî ãåìàòîëîãèè
      
 
Ðåãèñòðàöèÿ: 16.01.2003
Ãîðîä: Õüþñòîí, Òåõàñ
Ñîîáùåíèé: 80,291
Ïîáëàãîäàðèëè 33,189 ðàç(à) çà 31,539 ñîîáùåíèé
Dr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Ïðî ÎÎÎ âñå î÷åíü õîðîøî ðàñïèñàíî â íåäàâíåé ïóáëèêàöèè - êðîìå ñàìîãî íàëè÷èÿ ÎÎÎ, äîëæåí áûòü ïîäòâåðæäåí îáðàòíûé ñáðîñ, êðîìå âåíîçíûõ òðîìáîâ îòêóäà-áû-íè-áûëî èñòî÷íèêîì ýìáîëîâ ìîæåò áûòü: atrial septal defect, cardiac tumours (such as myxoma or papillary fibroelastoma), bacterial or non-bacterial valve vegetations, and atrial thrombi
---
BMJ. 2018; 362: k2515.
Published online 2018 Jul 25.
Patent foramen ovale closure, antiplatelet therapy or anticoagulation therapy alone for management of cryptogenic stroke? A clinical practice guideline
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
__________________
Èñêðåííå,
Âàäèì Âàëåðüåâè÷.
Îòâåòèòü ñ öèòèðîâàíèåì
  #7  
Ñòàðûé 08.08.2018, 18:29
Àâàòàð äëÿ Dr.Vad
Dr.Vad Dr.Vad âíå ôîðóìà
Ìîäåðàòîð ôîðóìà ïî ãåìàòîëîãèè
      
 
Ðåãèñòðàöèÿ: 16.01.2003
Ãîðîä: Õüþñòîí, Òåõàñ
Ñîîáùåíèé: 80,291
Ïîáëàãîäàðèëè 33,189 ðàç(à) çà 31,539 ñîîáùåíèé
Dr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Ñîãëàñíî ýòîé ðàáîòå èç Õüþñòîíà, ó ÷àñòè âçðîñëûõ ïàöèåíòîâ ñ èøåìè÷åñêèì èíñóëüòîì âûðàæåííàÿ ÆÄÀ ìîæåò áûòü åäèíñòâåííî-îáíàðóæèâàåìîé ïðè÷èíîé èíñóëüòà:

DESIGN/METHODS:
AIS patients with Hct <28% from July 2004 through March 2012 were identified from our stroke registry. Retrospective chart analysis was done to select patients with severe IDA defined by Hgb <10 g/dL with MCV <75 fL or ferritin <15 mcg/L or transferrin saturation <5%. Demographics, etiology, TPA treatment, MRI, blood transfusion, and cause of IDA were obtained.
RESULTS: Among 4,477 AIS patients, 147 subjects had Hct <28% and 39 met the criteria for severe IDA. Stroke mechanism could not be identified in 18 patients; median age 46.5 (±15) and 16 female and 2 male. 17 had positive DWI lesions and 1 unable to obtain MRI. 9 subjects received TPA; 1 had hemorrhagic transformation without TPA treatment. 61% IDA causes were from either menorrhagia or leiomyoma and 39% were either unknown or sickle cell disease. 14 subjects received RBC transfusion and 3 of 14 had resolution of deficit post-transfusion.
CONCLUSIONS: Prevalence of IDA is 1-20%; it is 3.9% in our AIS population and is often related to untreated uterine bleeding. As described in the pediatric population, severe IDA may be an underlying mechanism of ischemic stroke in adults, therefore, efforts must be undertaken to identify and treat the cause of the anemia. While patients with AIS and severe IDA may receive TPA, blood transfusion may be considered as an adjuvant therapy.

[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]

Ê ñîæàëåíèþ, òîëüêî òåçèñû, äåòàëè íåÿñíû, íî â ìîåì ïðåäñòàâëåíèè ãåìàòîêðèò ìåíåå 28% àññîöèèðóåòñÿ ñ ãåìîãëîáèíîì ìåíåå 85-90 ã/ë, íåïîíÿòíî, êàê èç 147 ïàöèåíòîâ ñ òàêèì ãåìàòîêðèòîì îíè îáíàðóæèëè âñåãî 39 ñ ãåìîãëîáèíîì ìåíåå 100 ïëþñ ÆÄ? Åñëè áû êðèòåðèåì ïåðâè÷íîãî îòáîðà áûë ãåìàòîêðèò ìåíåå 31-32, òî ôèíàëüíîå ÷èñëî ïàöèåíòîâ ñ ÆÄÀ áûëî áû âûøå; òàêæå ó áîëüøåé ïîëîâèíû (21) ïàöèåíòîâ ñ ÆÄÀ èíûå ïðè÷èíû èíñóëüòà áûëè óñòàíîâëåíû, òî åñòü ÆÄÀ áûëà àããðàâèðóþùèì ôàêòîðîì, áîëüøèíñòâî èç íèõ áûëè æåíùèíû ñ îáèëüíûìè ìåíñòð. ïîòåðÿìè (íåóêàçàííîé ýòèîëîãèè èëè îáóñëîâëåííûå ôèáðîìèîìàìè)

Êîììåíòàðèè ê ñîîáùåíèþ:
tis2 îäîáðèë(à): ñïàñèáî
__________________
Èñêðåííå,
Âàäèì Âàëåðüåâè÷.
Îòâåòèòü ñ öèòèðîâàíèåì
Îòâåò



Âàøè ïðàâà â ðàçäåëå
Âû íå ìîæåòå ñîçäàâàòü òåìû
Âû íå ìîæåòå îòâå÷àòü íà ñîîáùåíèÿ
Âû íå ìîæåòå ïðèêðåïëÿòü ôàéëû
Âû íå ìîæåòå ðåäàêòèðîâàòü ñîîáùåíèÿ

BB êîäû Âêë.
Ñìàéëû Âêë.
[IMG] êîä Âêë.
HTML êîä Âûêë.



×àñîâîé ïîÿñ GMT +3, âðåìÿ: 07:32.




Ðàáîòàåò íà vBulletin® âåðñèÿ 3.
Copyright ©2000 - 2024, Jelsoft Enterprises Ltd.